Choice of rDEN3Δ30/31-7164
DENGUE, VIRUS
The monovalent rDEN3Δ30/31-7164 is one of the four viral components of the tetravalent dengue vaccine candidate, TV003, developed by NIAID/NIH. It is derived from the wild-type DENV-3 Sleman/78 virus with 30 and 31 non-contiguous nucleotide deletions in the 3’ untranslated region (UTR) for attenuation, and a Vero cell adaptation mutation (nucleotide position 7164, corresponding to amino acid 115 in NS4B Val→Ala) [DENV3 is a clinically relevant and immunologically unique serotype, and the use of rDEN3Δ30/31-7164 in this trial will expand on previous work. Specifically, low levels of pre-existing anti-DENV antibodies enhance DENV3 while high levels are protective, making our trial an ideal model of both presentations [